AstraZeneca CEO says Summit drug could drive next generation of cancer combinations
AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics’ lead drug could help power next-generation cancer combinations that could be the “future of cancer care.”
CNBC’s Annika Kim Constantino has the latest.
